JMP Securities Maintains Market Outperform on Crinetics Pharmaceuticals, Raises Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben maintains a Market Outperform rating on Crinetics Pharmaceuticals (CRNX) and raises the price target from $50 to $60.
February 29, 2024 | 7:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities raises Crinetics Pharmaceuticals' price target from $50 to $60, maintaining a Market Outperform rating.
The increase in price target by JMP Securities from $50 to $60, while maintaining a Market Outperform rating, indicates a strong positive outlook on Crinetics Pharmaceuticals. This is likely to instill confidence among investors, potentially leading to a short-term increase in CRNX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100